发明名称 Methods for concomitant treatment of theophylline and febuxostat
摘要 The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.
申请公布号 US9107912(B2) 申请公布日期 2015.08.18
申请号 US201113227828 申请日期 2011.09.08
申请人 Takeda Pharmaceuticals U.S.A., Inc. 发明人 Gunawardhana Lhanoo;Tsai Max;Naik Himanshu
分类号 A61K31/522;A61K31/426;A61K31/415;A61K45/06 主分类号 A61K31/522
代理机构 Michael Best & Friedrich LLP 代理人 Mueller Lisa V.;Michael Best & Friedrich LLP
主权项 1. A method of treating hyperuricemia in a patient in need of treatment thereof, the method comprising the steps of: administering to a patient suffering from hyperuricemia and at least one second disease state, a therapeutically effective amount of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof, wherein the subject is also receiving concomitant administration of theophylline to treat the at least one second disease state, and further wherein (i) the administration of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof, to the patient does not result in theophylline toxicity to the patient; and (ii) administration of the theophylline is in an amount ranging from about 90% to about 110% of a manufacturer's recommended theophylline dosage amount in the absence of administration of at least one xanthine oxidoreductase inhibitor.
地址 Deerfield IL US